European Archives - Page 842 of 898 - European Medical Journal

Continue
EMJ
3 Mins
26th May 2015

Cardiovascular Nurses Discuss the Latest in Evidence Based Care

Sophia Antipolis, 24 May 2015 – The cardiovascular nursing event of the year is heading south to Croatia. EuroHeartCare is the official annual meeting of…
EMJ
4 Mins
26th May 2015

STOP-HF: Gene Therapy SDF-1 Remodels Hearts of High Risk Heart Failure Patients

Seville, Spain – 25 May 2015: The gene therapy SDF-1 remodelled the hearts of high risk heart failure patients in the phase II STOP-HF trial…
EMJ
1 Mins
26th May 2015

Conservative Management of Prostate Cancer: Favourable 15-Year Outcomes in Older Patients with Low-Risk Disease

SURVIVAL outcomes among patients with low-risk prostate cancer (PrC) are favourable when initially treated with conservative management…
EMJ
1 Mins
26th May 2015

Widespread Belief of Urine Sterility Put to the Sword

BACTERIA have been found in the bladders of healthy women, dispelling the myth that normal urine is sterile, according to new research from…
EMJ
2 Mins
22nd May 2015

Data Presented on Orsiro Hybrid Drug – El uting Stent at EuroPCR 2015 Highlights Safety and Efficacy in High – Risk Patients

PARIS, France, May 20, 2015—BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, today hosted a…
EMJ
21st May 2015

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
EMJ
21st May 2015

The mechanisms of BRCA-related breast cancer and molecular profiling

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…
EMJ
21st May 2015

Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial

Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.
EMJ
21st May 2015

The role of BRCA and PARP in DNA repair and BRCA-related breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
EMJ
21st May 2015

The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…